Skip to main content

Advertisement

Table 1 Patient Characteristics

From: Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

  FOLFOX-4 (n = 29) Topotecan (n = 26) P
  N (%) N (%)  
Median age, years (range) 60 (33–85) 66 (51–80) 0.032
Histology
 Serous 22 (75.9) 22 (84.6)  
 Non-serous 7 (24.1) 4 (15.4) 0.422
FIGO stage at presentation
 I-II 3 (14.3) 2 (12.5)  
 III 16 (76.2) 11 (68.7)  
 IV 2 (9.5) 3 (18.8) 0.529
 Unknown/missing 8 10  
Grade
 I 5 (20.8) 7 (29.2)  
 II 5 (20.8) 4 (16.7)  
 III 14 (58.4) 13 (54.1) 0.612
 Unknown/missing 5 2  
ECOG Perfomance status
 0–1 27 (93.1) 25 (96.1)  
 2 2 (6.9) 1 (3.9) 0.622
Sites of metastasis
 Only abdominal 11 (37.9) 20 (76.9)  
 Abdominal + extra-abdominal 18 (62.1) 6 (23.1) 0.004
Number of involved sites
 1 4 (13.8) 5 (19.2)  
 2 10 (34.5) 10 (38.5)  
  ≥ 3 15 (51.7) 11 (42.3) 0.459
Median interval from initial diagnosis, months (range) 47 (11.5–248) 40.4 (9.7–1301) 0.129
Lines of previous treatments
  ≤ 4 15 (51.7) 20 (76.9)  
  > 4 14 (48.3) 6 (23.1) 0.055
Number of treatment cycles
 Median value (range) 4 (1–17) 3 (1–8) 0.038
Baseline NLR
  < 3 13 (46.4) 20 (80.0)  
  ≥ 3 15 (53.6) 5 (20.0) 0.013
 Unknown/missing 1 1  
Baseline PLR
  < 210 13 (46.4) 18 (72.0)  
  ≥ 210 15 (53.6) 7 (28.0) 0.062
Unknown/missing 1 1  
Median baseline Hb, g/dL (range) 11.1 (8.3–15.0) 12.1 (8.9–14.3) 0.058
Median baseline Ca125, ng/mL (range) 289.9 (13.3–11,344.0) 100.2 (12.6–10,805.0) 0.259
Median baseline BMI, kg/m2 (range) 23.88 (15.24–32.04) 23.16 (19.53–30.30) 0.345
  1. Abbreviation. BMI body mass index, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil, Hb hemoglobin, NL ,neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio